Motley Fool
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment
📈
AI Sentiment
Highly Positive
9/10
- Home
- UTHR
as of 03-18-2026 3:40pm EST
$531.38
$8.64
-1.60%
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 23.9B | IPO Year: | 1999 |
| Target Price: | $531.79 | AVG Volume (30 days): | 477.5K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 27.86 | EPS Growth: | 13.07 |
| 52 Week Low/High: | $266.98 - $548.12 | Next Earning Date: | 04-29-2026 |
| Revenue: | $1,483,300,000 | Revenue Growth: | 2.38% |
| Revenue Growth (this year): | 7.77% | Revenue Growth (next year): | 11.11% |
| P/E Ratio: | 19.04 | Index: | N/A |
| Free Cash Flow: | 1.0B | FCF Growth: | -3.69% |
AI-Powered UTHR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.33%
69.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
MALCOLM JAN
Sell
Director
UTHR Mar 17, 2026
Avg Cost/Share
$533.51
Shares
45
Total Value
$24,007.95
Owned After
125
SEC Form 4
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Mar 16, 2026
Avg Cost/Share
$533.68
Shares
10,016
Total Value
$5,348,072.15
Owned After
49,653
Olian Judy D.
Sell
Director
UTHR Mar 16, 2026
Avg Cost/Share
$535.44
Shares
200
Total Value
$107,088.00
Owned After
4,445
SEC Form 4
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Mar 13, 2026
Avg Cost/Share
$538.77
Shares
9,500
Total Value
$5,110,966.75
Owned After
49,653
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Mar 12, 2026
Avg Cost/Share
$538.74
Shares
8,984
Total Value
$4,833,095.14
Owned After
49,653
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Mar 11, 2026
Avg Cost/Share
$539.21
Shares
9,500
Total Value
$5,125,646.80
Owned After
49,653
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Mar 10, 2026
Avg Cost/Share
$539.35
Shares
9,500
Total Value
$5,127,273.03
Owned After
49,653
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Mar 9, 2026
Avg Cost/Share
$518.35
Shares
9,500
Total Value
$4,921,275.42
Owned After
49,653
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Mar 6, 2026
Avg Cost/Share
$478.41
Shares
9,500
Total Value
$4,537,852.66
Owned After
49,653
Olian Judy D.
Sell
Director
UTHR Mar 6, 2026
Avg Cost/Share
$510.00
Shares
200
Total Value
$102,000.00
Owned After
4,445
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MALCOLM JAN | UTHR | Director | Mar 17, 2026 | Sell | $533.51 | 45 | $24,007.95 | 125 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Mar 16, 2026 | Sell | $533.68 | 10,016 | $5,348,072.15 | 49,653 | |
| Olian Judy D. | UTHR | Director | Mar 16, 2026 | Sell | $535.44 | 200 | $107,088.00 | 4,445 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Mar 13, 2026 | Sell | $538.77 | 9,500 | $5,110,966.75 | 49,653 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Mar 12, 2026 | Sell | $538.74 | 8,984 | $4,833,095.14 | 49,653 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Mar 11, 2026 | Sell | $539.21 | 9,500 | $5,125,646.80 | 49,653 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Mar 10, 2026 | Sell | $539.35 | 9,500 | $5,127,273.03 | 49,653 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Mar 9, 2026 | Sell | $518.35 | 9,500 | $4,921,275.42 | 49,653 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Mar 6, 2026 | Sell | $478.41 | 9,500 | $4,537,852.66 | 49,653 | |
| Olian Judy D. | UTHR | Director | Mar 6, 2026 | Sell | $510.00 | 200 | $102,000.00 | 4,445 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 25, 2026 · 99% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 25, 2026 · 99% conf.
AI Prediction SELL
1D
-1.51%
$527.02
Act: -5.89%
5D
-2.60%
$521.18
Act: -8.39%
20D
-0.86%
$530.52
Price: $535.10 Prob +5D: 1% AUC: 1.000
0001082554-26-000007
uthr-202602250001082554false00010825542026-02-252026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2026
United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter)
Delaware000-2630152-1984749 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)
1000 Spring Street Silver Spring,
MD20910
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (301) 608-9292
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered Common Stock, par value $0.01 per shareUTHRNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 25, 2026, United Therapeutics Corporation issued a press release setting forth its earnings and business updates for the quarter and year ended December 31, 2025.
A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Exhibits
This information shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
(d) Exhibits
Exhibit No. Description of Exhibit
99.1 Press Release dated February 25, 2026, related to the Company's fourth quarter and full year 2025 earnings.
104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UNITED THERAPEUTICS CORPORATION
Dated: February 25, 2026By:/s/ Paul A. Mahon Name:Paul A. Mahon Title:General Counsel
2025 Q3 Q3 2025 Earnings
8-K Oct 29, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 29, 2025
0001082554-25-000036
uthr-202510290001082554false00010825542025-10-292025-10-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2025
United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter)
Delaware000-2630152-1984749 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)
1000 Spring Street Silver Spring,
MD20910
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (301) 608-9292
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered Common Stock, par value $0.01 per shareUTHRNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On October 29, 2025, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended September 30, 2025.
A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Exhibits
This information shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
(d) Exhibits
Exhibit No. Description of Exhibit
99.1 Press Release dated October 29, 2025
104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UNITED THERAPEUTICS CORPORATION
Dated: October 29, 2025By:/s/ Paul A. Mahon Name:Paul A. Mahon Title:General Counsel
2025 Q2 Q2 2025 Earnings
8-K Jul 30, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 30, 2025
0001628280-25-036543
uthr-202507300001082554false00010825542025-07-302025-07-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2025
United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter)
Delaware000-2630152-1984749 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)
1000 Spring Street Silver Spring,
MD20910
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (301) 608-9292
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered Common Stock, par value $0.01 per shareUTHRNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 30, 2025, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended June 30, 2025.
A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Exhibits
This information shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
(d) Exhibits
Exhibit No. Description of Exhibit
99.1 Press Release dated July 30, 2025
104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UNITED THERAPEUTICS CORPORATION
Dated: July 30, 2025By:/s/ Paul A. Mahon Name:Paul A. Mahon Title:General Counsel
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Motley Fool
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock
➖
AI Sentiment
Neutral
4/10
MT Newswires
United Therapeutics Insider Sold Shares Worth $5,109,148, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
Simply Wall St.
Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential
📈
AI Sentiment
Highly Positive
9/10
Zacks
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
📈
AI Sentiment
Highly Positive
10/10
Compare UTHR vs Leading Stocks
See how UTHR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.